TriSalus Life Sciences, Inc.
TLSINasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $45.2M | $29.4M | $18.5M | $12.4M | — | — |
| Operating income | −$26.9M | −$11.7M | −$54.5M | −$36.4M | −$3.0M | −$108,493 |
| Net income | −$39.2M | −$13.2M | −$59.4M | −$47.2M | $4.8M | −$711,389 |
| Total assets | $35.3M | $24.0M | $24.6M | $22.0M | $250.5M | $252.0M |
| Total liabilities | $69.2M | $49.9M | $51.7M | $34.3M | $17.3M | $23.5M |
| Equity | −$33.9M | −$25.9M | −$27.1M | −$177.1M | −$129.6M | $0 |
| EPS (diluted) | $-1.84 | $-0.60 | $-6.77 | $-161.55 | — | — |
| Shares out. | 32.3M | 26.8M | 26.3M | 347,926 | — | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −59.7%
- Net margin
- −86.9%
- Return on equity
- 115.8%
- Return on assets
- −111.0%
- Return on capital (ROCE)
- −113.1%
- Liabilities / assets
- 195.8%
- Debt / equity
- —
- Book value / share
- $-1.05
- Revenue growth (YoY)
- 53.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -32.29distress
- Accruals / assets
- −60.0%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 28, 2025
- NT 10-Kmissed a reporting deadline ↗Apr 2, 2024
- NT 10-Qmissed a reporting deadline ↗May 17, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Pallotta James JPassive (13G)May 20, 2026
- First Light Asset Management, LlcPassive (13G)May 15, 2026
- Utmost Group PlcPassive (13G)May 12, 2026
- Nantahala Capital Management, LlcPassive (13G)Nov 14, 2025
- Frankenius Equity AbActivist (13D)Aug 4, 2025
- Wahlstrom MatsActivist (13D)Aug 1, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Marshak RichardOfficer — Chief Commercial Officer | May 15, 2026 | Sell | 543 | $2.67 |
| Wahlstrom MatsDirector | May 15, 2026 | Buy | 60,000 | $2.53 |
| Stansky Michael PDirector | May 15, 2026 | Buy | 410,000 | $2.50 |
| Szela Mary TOfficer — CEO and President | May 15, 2026 | Buy | 39,682 | $2.59 |
| Patience DavidOfficer — Chief Financial Officer | May 15, 2026 | Buy | 7,100 | $2.43 |
| Gordon Gary B.Director | May 15, 2026 | Buy | 10,000 | $2.46 |
| Hicks Kerry RDirector | May 14, 2026 | Grant | 28,201 | $0.00 |
| Wahlstrom MatsDirector | May 14, 2026 | Grant | 37,602 | $0.00 |
| Gordon Gary B.Director | May 14, 2026 | Grant | 28,201 | $0.00 |
| Matlin David JDirector | May 14, 2026 | Grant | 28,201 | $0.00 |
| Valle WilliamDirector | May 14, 2026 | Grant | 28,201 | $0.00 |
| Stansky Michael PDirector | May 14, 2026 | Grant | 23,501 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.7M | 1.6 | +16.8% |
| Apr 30, 2026 | 1.4M | 12.3 | +9.0% |
| Apr 15, 2026 | 1.3M | 8.8 | +10.5% |
| Mar 31, 2026 | 1.2M | 5.9 | +10.9% |
| Mar 13, 2026 | 1.1M | 4.3 | +9.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 14, 2026
- Results of operationsMay 12, 2026
- Director / officer changeApr 29, 2026
- Director / officer change · Regulation FD disclosureApr 7, 2026
- Results of operationsMar 5, 2026
- Entered a material agreement · Other material eventFeb 20, 2026
- Director / officer change · Regulation FD disclosureFeb 9, 2026
- Results of operationsJan 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (4)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.